Efficacy & Safety of Ravidasvir + Sofosbuvir in Hepatitis C: STORM-C-1 Final Results

Soek-Siam Tan1, Sombat Thanprasertsuk2, Satawat Thongsawat3, Nicolas Salvadori4, Caroline Menetrey5, STORM-C-1 Research Team*

*STORM-C-1 Research Team: Hajjah Rosaida Hj Mohd Said1, Muhammad Radzi Abu Hassan2, Haniza Omar3, Wah Kheong Chan9, Mahiran Mustafa10, Muhammad Firdaus Md Salleh11, Syuhada Dan Binti Adnan12, Isabelle Andrieux-Meyer13, Bernard Pécoul13, François Bompard13, Laurent Brachet13, Vishal Goyal13, Isabela Ribeiro13, François Simon13, Sasikala Siva13, Alistair Swanson13, Tim R Cressey14, Nicole Ngo-Giang-Huong15, Sabine Yerly16, Shahnaz Murad17

1Hospital Ampang, Malaysia; 2Hospital Sultanah Bahiyah, Malaysia; Hospital Salaya, Malaysia; Thai Red Cross AIDS Research Centre; 3Barranwarata Infectious Diseases Institute, Norththai, Thailand; 4Auckland Hospital, New Zealand; 5Chiang Mai University, Thailand; 6Nakorn Chiao Chiang Mai Hospital, Chiang Mai, Thailand; 7Hospital Tungpja Ampun-Atna Malaysia; 8Hospital Sungai Buloh, Malaysia; 9University of Malaya, Faculty of Medicine, Malaysia; 10Hospital Raja Perempuan Zainab Il., Kota Bharu, Malaysia; 11Hospital Subhanah Amnah, Department of Medicine, Johor Bahru, Malaysia; 12Hospital Subnah Nizam, Zafarain, Department of Hepatology/Gastroenterology, Kuala Lumpur, Malaysia; 13Drugs for Neglected Diseases initiative, Geneva, Switzerland; 14Chiang Mai University, Faculty of Associated Medical Sciences, PhPT/IRD, Chiang Mai, Thailand; 15Ministry of Health, Kuala Lumpur, Malaysia

BACKGROUND
Affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection in low and middle-income countries. STORM-C-1 study aimed to assess the efficacy and safety of ravidasvir plus sofosbuvir in adults chronically infected with HCV, with or without HIV coinfection.

METHODS
Trial design: Two-stage, open-label, phase 2/3 single-arm clinical trial conducted in 13 public hospitals in Malaysia and Thailand.
Participants: Chronic HCV infection, aged 18–69 years, without cirrhosis or with compensated cirrhosis (Child-Turcotte-Pugh class A), regardless of HCV genotype, HIV infection status or previous interferon-based HCV treatment.
Treatments: Once daily ravidasvir (200 mg) and sofosbuvir (400 mg) – 12 weeks for participants without cirrhosis or 24 weeks for those with cirrhosis.
Primary endpoint: Sustained virological response at 12 weeks after treatment (SVR12), defined as HCV RNA < LLOQ (<15 IU/mL in Malaysian and <12 IU/mL in Thai sites).

RESULTS
Baseline characteristics: Between September 2016 and September 2020, 603 participants were enrolled in STORM-C-1. Of these, 296 (49%) had genotype 3 infection, 162 (27%) had genotype 1a, 81 (13%) had genotype 1b, 61 (10%) had genotype 6 and 3 (<1%) had genotype 2. 238 (39%) had compensated cirrhosis, 192 (32%) had HIV co-infection, and 120 (20%) had received previous interferon-based treatment.

SVR by visit during post treatment period

Full analysis set (n=602)

Visit | SVR | 95% CI of SVR
--- | --- | ---
Follow-up Wk 4 | 586/602 (97.3%) | 95.7% to 98.5%
Follow-up Wk 12 | 583/602 (96.8%) | 95.1% to 98.1%
Follow-up Wk 24 | 580/602 (96.3%) | 94.5% to 97.7%

Overall SVR12 rate in per protocol set (n=580): 98.1% (95% CI: 96.6% to 99.0%). There were no significant drug-drug interactions with anti-retroviral therapies.

Sustained virological response at 12 weeks post-treatment – Full analysis set (n=602)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Any TEAE</th>
<th>Treatment related</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3 TEAE</td>
<td>Any TEAE</td>
<td>16 (4%) [41]</td>
<td>17 (7%) [26]</td>
</tr>
<tr>
<td>Treatment related</td>
<td>2 (1%) [2]</td>
<td>3 (1%) [7]</td>
<td>5 (1%) [9]</td>
</tr>
<tr>
<td>Grade 4 TEAE</td>
<td>Any TEAE</td>
<td>1 (&lt;1%) [1]</td>
<td>1 (&lt;1%) [1]</td>
</tr>
<tr>
<td>Treatment related</td>
<td>0 (0%) [0]</td>
<td>0 (0%) [0]</td>
<td>0 (0%) [0]</td>
</tr>
<tr>
<td>Deaths</td>
<td>Any deaths</td>
<td>0 (0%) [0]</td>
<td>1 (&lt;1%) [1]</td>
</tr>
<tr>
<td>Treatment related</td>
<td>0 (0%) [0]</td>
<td>0 (0%) [0]</td>
<td>0 (0%) [0]</td>
</tr>
</tbody>
</table>

Primary safety endpoints:

- Treatment Emergent Adverse Events (TEAE) - Safety set (n=603)
- TEAEs: Any TEAE: 16 (4%) [41] 17 (7%) [26] 33 (5%) [67]
- Treatment related: 2 (1%) [2] 3 (1%) [7] 5 (1%) [9]
- Deaths: Any deaths: 0 (0%) [0] 1 (<1%) [1] 1 (<1%) [1]
- Treatment related: 0 (0%) [0] 0 (0%) [0] 0 (0%) [0]

Overall SVR12 rate: 98.1% (95% CI: 96.6% to 99.0%). There were no significant drug-drug interactions with anti-retroviral therapies.

Adverse Events
Most common AEs: pyrexia (8%), URTI (6%), cough (6%), dizziness (5%), headache (5%).
One treatment emergent serious adverse event of acute kidney injury was assessed as possibly related to study treatment (sofosbuvir).

Treatment Emergent Adverse Events (TEAE) - Safety set (n=603)

Two additional deaths occurred after the 24-week post-treatment visit: both were unrelated to study treatment or to liver disease.

CONCLUSIONS
In this study, Ravidasvir with sofosbuvir was well tolerated with excellent safety and efficacy in chronic HCV infection, including in difficult-to-treat populations (GT3, cirrhosis, prior HCV treatment, HIV co-infection).